Insights on the Ankylosing Spondylitis Global Market to 2030 - Rise in Number of Hospitals and Diagnostic Centers is Driving Growth
05. Mai 2022 08:08 ET
|
Research and Markets
Dublin, May 05, 2022 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis Market by Drug Class and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been...
Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
20. Juli 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China.Sorrento holds commercialization rights outside of China and intends to meet...
Global Crohn's Disease Forecast and Market Analysis Report 2020-2027 - Despite Formulary Constraints, Novel Pipeline Drugs will Expand the Market
12. Januar 2021 07:03 ET
|
Research and Markets
Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Crohn's Disease Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering. As specialty products, therapies...
Global Ankylosing Spondylitis Market Outlook Report 2019-2027: Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities
21. Dezember 2020 10:53 ET
|
Research and Markets
Dublin, Dec. 21, 2020 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. Global Ankylosing Spondylitis...
Global Ankylosing Spondylitis Market Outlook to 2027: High Treatment Cost and Lack of Skilled Surgeons and Physiotherapists are Hampering Market Growth
04. November 2020 04:43 ET
|
Research and Markets
Dublin, Nov. 04, 2020 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. Global Ankylosing Spondylitis...
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China
06. Januar 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab...